Cancer drug trial aims to shrink HIV's hiding spots
NCT ID NCT07481175
Summary
This early-stage study is testing whether adding a cancer drug called venetoclax to standard HIV medication (ART) when treatment is first started can help kill more infected cells. The goal is to shrink the hidden pool of virus that persists even with regular therapy, which could lead to better long-term control. Researchers will check if this approach is safe and measure its effect on the amount of hidden virus in the blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Universitari Germans Trias I Pujol, Department of Infectious Diseases
Badalona, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Infectious Diseases, Q Research
Aarhus, 8200, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.